{"entity":{"id":"cyclacel","kind":"company","name":"Cyclacel Pharmaceuticals","aka":["Cyclacel Pharmaceuticals, Inc.","Cyclacel"],"tldr":"Cyclacel is a cell-cycle drug company whose nucleoside analogue sapacitabine failed its phase 3 trial in older patients with acute myeloid leukaemia; it now develops CDK and PLK inhibitors.","summary":"Cyclacel Pharmaceuticals, founded in 1997 with roots in Dundee and headquartered in Berkeley Heights, New Jersey, ran the phase 3 SEAMLESS trial of oral sapacitabine alternating with decitabine in elderly acute myeloid leukaemia, which did not meet its survival endpoint. It continues with the CDK2/9 inhibitor fadraciclib and a PLK1 inhibitor in early trials, registered on ClinicalTrials.gov under Cyclacel as lead sponsor.","asOf":"2026-09-11","links":[{"label":"Official website","url":"http://www.cyclacel.com"},{"label":"ClinicalTrials.gov: trials led by Cyclacel Pharmaceuticals, Inc.","url":"https://clinicaltrials.gov/search?lead=Cyclacel%20Pharmaceuticals%2C%20Inc."},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q5198104"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["aml"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Berkeley Heights, NJ","country":"US","companyType":"biotech","website":"http://www.cyclacel.com","founded":1997,"stage":"public","investors":[],"funding":[]},"route":"/companies/cyclacel/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"}],"term":[{"id":"clinical-trial","kind":"term","name":"Clinical trial","route":"/terms/clinical-trial/"},{"id":"pivotal-trial","kind":"term","name":"Pivotal (registrational) trial","route":"/terms/pivotal-trial/"}]}}